Companies / BOC Sciences / Alemtuzumab
BOC Sciences

Alemtuzumab | BOC Sciences

Alemtuzumab is a monoclonal antibody directed against CD52. Alemtuzumab is indicated for the treatment of B-cell chronic lymphocytic leukemia and relapsing multiple sclerosis.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.